Christopher P. Cannon, MD, FACC

General Statement of Disclosure:

CONSULTING FEES/HONORARIA: BMS(MODEST), Boehringer-Ingelheim(SIGNIFICANT), Kowa(MODEST), Pfizer (MODEST), Regeneron/Sanofi(SIGNIFICANT), Alnylam(MODEST), Amgen(SIGNIFICANT), Amarin(MODEST), Merck(SIGNIFICANT), Eisai(MODEST) RESEARCH/RESEARCH GRANTS: Boehringer-Ingelheim(SIGNIFICANT), Janssen Pharmaceuticals, Inc(SIGNIFICANT), BMS(SIGNIFICANT), Merck(SIGNIFICANT), Amgen(SIGNIFICANT), Daiichi Sankyo(SIGNIFICANT)

View Full Disclosure